BioSpace News Archive

Cardiawave SA announced the publication of results from its First-In-Human clinical studies on 40 patients suffering from CAS treated with its NIUT in The Lancet and the completion of the enrollment of 60 patients in its “Valvosoft® pivotal study”.

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference Tuesday, November 28 at 1:45 pm EST (10:45 am PST/6:45 pm GMT) and will be hosting in-person meetings with the investment community at the conference.

The Department of Biomedicine at the University of Basel and the University Hospital Basel, announced that it delivered the first surgical procedure to treat Osteoarthritis in humans.

Kite, a Gilead Company, and Arcellx, Inc., announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.

Proxygen, a leader in the discovery and development of molecular glue degraders, announced the formation of the company’s scientific advisory board.

Olink Holding AB announced its unaudited financial results for the third quarter ended September 30, 2023.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, provided a business update and announced financial results for the third quarter ended September 30, 2023.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced the completion of the clinical phase of the Phase 3 registration-quality, double-blind, placebo-controlled RESILIENT1 study of TNX-102 SL2 (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia.

Mural Oncology plc launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers.

LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.